CERENOVUS launches next generation catheter for revascularization of patients with acute ischemic stroke

CERENOVUS, part of Johnson & Johnson MedTech, has announced the launch of CEREGLIDE 71 Intermediate Catheter, a next-generation intermediate catheter with TruCourse Technology indicated for the revazcularisation of patients suffering from acute ischemic stroke.  

Acute ischemic strokes account for 85% of all strokes worldwide. By utilising aspiration catheters during thrombectomy procedures, physicians can restore blood flow in the brain by directly withdrawing a blood clot or using the catheter in combination with a stent retriever. However, in nearly 50% of cases, challenging features, such as anatomy, can impact assess to the clot, procedure time, recanalisation success and clinical outcomes. 

CEREGLIDE 71 Intermediate Catheter is equipped with TruCourse Technology to increase flexibility of the device and is designed to help physicians with improved navigation and access to clots, even in challenging anatomical conditions. Part of CERENOVUS STROKE SOLUTIONS, CEREGLIDE 71 Intermediate Catheter with TruCourse provides physicians with optimal compatibility, durable delivery and reliable trackability during thrombectomy procedures. 

“In the rapidly evolving landscape of neuroendovascular stroke care, staying on the cutting edge is crucial for advancing the field and ensuring physicians have the tools to navigate complex patient anatomy” said Fawaz Al-Mufti, MD, Interventional Neurologist, Director of the Neuroendovascular Surgery Fellowship, Westchester Medical Center/New York Medical College.